Axsome Therapeutics is expected to report Q3 2026 revenue of $249.19 million and an EPS loss of $0.68, with shares currently trading at $140.99 compared to an average analyst price target of $280.33. Investors are primarily focused on the commercial trajectory of Auvelity, especially its expansion into the Alzheimer's disease agitation market following its June 2026 launch.
Analysts are monitoring whether the strong prescription growth for Auvelity and Sunosi can significantly narrow net losses as the company scales. Additionally, progress on the late-stage pipeline, including regulatory filings for AXS-12 in narcolepsy, remains a critical component of Axsome’s path toward projected profitability in 2027.